IL-12 |
Enhanced IFN-γ secretion
Increased survival/persistence
Decreased apoptosis
Enhanced proliferation
Reduction of tumour associated macrophages
Enhanced resistance to PDL-1 inhibition
Recruitment of immune cells
|
Koneru et al54 Pegram et al55 Yeku et al56 Chmielewski et al57 Liu et al58 Sachdeva et al60 Kueberuwa et al61
|
IL-15 |
Promotes naïve and central memory phenotypes
Increased expression of anti-apoptotic proteins
Reduced expression of exhaustion markers
Enhanced natural killer cell activation
Reduced tumour associated macrophage accumulation
Enhanced expansion, persistence and increased stem cell memory populations when expressed in combination with IL-21
|
Lanitis et al62 Markley et al63 Batra et al66
|
IL-7 and CCL19 |
|
Adachi et al65
|
IL-7 |
|
Markley et al63
|
IL-21 |
|
Markley et al63 Batra et al66
|
IL-9 |
|
Liu et al67
|
IL-18 |
|
Hu et al68 Chmielewski et al69
|
IL-23 |
Enhanced proliferation
Increased granzyme B secretion
Reduced expression of exhaustion markers
Reduced toxicity compared to IL-15 and IL-18 armoured CARs
|
Ma et al70
|
IL-24 |
|
Hu et al71
|
IL-36-γ |
Enhanced expansion and persistence
Increased dendritic cell secretion of IL-6
Increased endogenous T cell secretion of IFN-γ and TNF-α
|
Li et al72
|
Cytokine receptor |
|
|
IL-6R (gp130 expression) |
|
Jiang et al73
|
IL-7R |
Enhanced proliferation
Enhanced survival
|
Shum et al74 Zhao et al75 Perna et al76
|
IL-4αβ switch receptor |
|
Wilkie et al77
|
IL-4/7 switch receptor |
|
Leen et al78 Mohammed et al79
|
IL-4/21 switch receptor |
|
Wang et al80
|
c-fms |
|
Lo et al83
|